Demo
ANTH OTCM· Anthera Pharmaceuticals Inc.
FundamentalsNews digest Peer analysis
Login
ANTH OTCM· Anthera Pharmaceuticals Inc.
Earnings report Q1 2018

ANTH Reports Decrease in Revenue for the Latest Quarter

Segments of revenue

ANTH reported a decrease in revenue for the latest quarter. The company's revenue for the quarter ended March 31, 2018 was not provided in the given context.

Strengths

Despite the decrease in revenue, ANTH's management highlighted several strengths in their discussion of financial condition and results of operations. They mentioned that the decrease in revenue was primarily due to the completion of certain clinical studies, which resulted in a decrease in collaboration revenue. However, ANTH's management expressed confidence in the potential of their product candidates and highlighted the progress made in their ongoing clinical trials. They also mentioned that they have sufficient cash and cash equivalents to fund their operations for at least the next twelve months.

Challenges

The decrease in revenue for the latest quarter is a significant challenge for ANTH. The completion of certain clinical studies and the resulting decrease in collaboration revenue impacted their overall financial performance. Additionally, ANTH reported a net loss of $7.72 million for the quarter, which further highlights the challenges they are facing.

Noteworthy

It is worth mentioning that ANTH's management emphasized the progress made in their ongoing clinical trials. They highlighted positive results from their Phase 2 clinical trial for one of their product candidates, which showed potential benefits for patients with a certain medical condition. This noteworthy development could have a positive impact on ANTH's future revenue and financial performance.

Summary

ANTH reported a decrease in revenue for the latest quarter, primarily due to the completion of certain clinical studies. Despite this decrease, ANTH's management expressed confidence in their product candidates and highlighted positive results from ongoing clinical trials. However, the company's net loss for the quarter and the challenges they are facing in terms of revenue generation indicate a need for continued focus on improving their financial performance.

Source documents

Form 10-Q  filed on May 15, 2018
36 pages scanned

Reference data

Company financials Q1 revenue 0
Analyst estimates Q1 EPS missed by -100.00%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.